Published in J Clin Densitom on August 03, 2011
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis (2012) 1.02
Fracture risk assessment without race/ethnicity information. J Clin Endocrinol Metab (2012) 0.93
Ethnic variability in bone geometry as assessed by hip structure analysis: findings from the hip strength across the menopausal transition study. J Bone Miner Res (2013) 0.84
The Chinese skeleton: insights into microstructure that help to explain the epidemiology of fracture. Bone Res (2014) 0.80
Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women. BMC Musculoskelet Disord (2016) 0.79
The discriminative ability of FRAX, the WHO algorithm, to identify women with prevalent asymptomatic vertebral fractures: a cross-sectional study. BMC Musculoskelet Disord (2014) 0.79
Systemic markers of microvascular disease and bone mineral density in older adults : The cardiovascular health study. Osteoporos Int (2016) 0.78
Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int (2015) 0.78
Osteoporosis in men: a review. Bone Res (2014) 0.78
The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone (2017) 0.75
Cortical microstructure compensates for smaller bone size in young Caribbean Hispanic versus non-Hispanic white men. Osteoporos Int (2017) 0.75
The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs (2017) 0.75
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Dynamic visualization of thrombopoiesis within bone marrow. Science (2007) 4.35
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Patient Mortality Is Associated With Staff Resources and Workload in the ICU: A Multicenter Observational Study. Crit Care Med (2015) 3.49
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Vitamin D insufficiency in a population of healthy western Canadians. CMAJ (2002) 2.73
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab (2002) 2.69
Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom (2008) 2.64
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell (2010) 2.42
Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab (2012) 2.41
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res (2010) 2.34
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat Rev Endocrinol (2010) 2.14
The perspective of the international osteoporosis foundation on the official positions of the international society for clinical densitometry. J Clin Densitom (2005) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One (2011) 2.13
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
Tooth count in elderly women in relation to their skeletal status. Maturitas (2006) 1.98
Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet (2004) 1.97
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis (2011) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Noncancer disease incidence in atomic bomb survivors, 1958-1998. Radiat Res (2004) 1.89
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood (2008) 1.86
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res (2011) 1.86
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis (2011) 1.86
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res (2012) 1.84
Which fractures are most attributable to osteoporosis? J Clin Epidemiol (2011) 1.84
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med (2003) 1.81
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res (2007) 1.79
Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res (2006) 1.78
Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J Bone Miner Res (2010) 1.78
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet (2011) 1.75
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
Can hospital discharge databases be used to follow ischemic stroke incidence? Stroke (2013) 1.73
Greater trochanteric pain syndrome: epidemiology and associated factors. Arch Phys Med Rehabil (2007) 1.72
Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J (2009) 1.72
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res (2011) 1.72
Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res (2009) 1.71
Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart (2006) 1.69
Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos (2012) 1.69
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause (2012) 1.66
Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med (2007) 1.63
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Nutrient intake and anemia risk in the women's health initiative observational study. J Am Diet Assoc (2011) 1.60